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Abstract: 
 
Enniatins are cyclohexadepsipeptides isolated largely from Fusariumspecies of fungi, although 
they have been isolated from other genera, such as Verticillium and Halosarpheia. They were 
first described over 60 years ago, and their range of biological activities, including antiinsectan, 
antifungal, antibiotic and cytotoxic, drives contemporary interest. To date, 29 enniatins have 
been isolated and characterized, either as a single compound or mixtures of inseparable 
homologs. Structurally, these depsipeptides are biosynthesized by a multifunctional enzyme, 
termed enniatin synthetase, and are composed of six residues that alternate between N-methyl 
amino acids and hydroxy acids. Their structure elucidation can be challenging, particularly for 
enniatins isolated as inseparable homologs; however, several strategies and tools have been 
utilized to solve these problems. Currently, there is one drug that has been developed from a 
mixture of enniatins, fusafungine, which is used as a topical treatment of upper respiratory tract 
infections by oral and/or nasal inhalation. Given the range of biological activities observed for 
this class of compounds, research on enniatins will likely continue. This review strives to digest 
the past studies, as well as, describe tools and techniques that can be utilized to overcome the 
challenges associated with the structure elucidation of mixtures of enniatin homologs. 
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Article: 
 
Introduction and history of enniatins 
 
Enniatins are cyclohexadepsipeptides composed of alternating residues of three N-methyl amino 
acids, commonly valine (Val), leucine (Leu), and isoleucine (Ile), and three hydroxy acids, 
typically hydroxyisovaleric acid (Hiv). These secondary metabolites have been observed 
frequently from Fusarium species of fungi, although they have been isolated from a few other 
genera as well (Table 1). The first enniatin (enniatin A (1)) was reported from the 
fungus Fusarium orthoceras var. enniatinum by Gaumann et al.1 in 1947, and 1 was shown to be 
active against several mycobacteria in vitro. Shortly thereafter, another group working 
independently, isolated a compound they named lateritiin-I from Fusarium lateritium, which was 
found to be identical to 1.2, 3 In 1974, Audhya and Russel4 identified that previously reported 
enniatin A was actually a mixture of threo and erythro optical isomers. At that time only enniatin 
B had been observed pure from a natural source.5 Scientists worked to scale up the production of 
enniatin A, largely for the purpose of studying its ionophoric properties, which had started to 
emerge as the probable mechanism of action for enniatins.5 One isolation study4, 6 yielded a 
mixture of enniatins A (1), A1 (3), B (2) and B1 (4), while an earlier insecticidal assay-guided 
study revealed that an enniatin A- and A1-rich complex was the active component in a fraction 
toxic to spruce budworm larvae.7 However, in 1992 the first report on the purification of 
enniatins A (1), A1 (3), B (2), B1 (4) and new analog A2 (5),8 was published. From that point on, 
the isolation and characterization of enniatins expanded to include: enniatins B2 (6), B3 (7) and 
B4 (8)9 (D (8), which has the same structure as B4, was published in the same year);10 C 
(9);11 E1(10), E2 (11) and F (12);10 G (13);12 H (14) and I (15) together with biosynthesized 
analogs G (13), C (9) and MK1688 (16);13 J1 (17), J2 (18), J3(19) and K1 (20);14 L (21), M1 (22), 
M2 (23) and N (24);15 O1 (25), O2 (26) and O3 (27);11 and most recently, P1 (28) and 
P2 (29).16 Enniatin C (9) was reported first as a synthetic product,4 then as a biosynthetic 
product,13 before it was isolated as a natural product.11 
 
Table 1. Sources and bioactivities of enniatins derived from the literature 
Enniatin Biological sourcea Bioactivities 
A (1) Fusarium avenaceum;
50  
Fusarium sp. FO-130510 Cytotoxic against Hep G2, MRC-5; ACAT inhibition 
A1 (3) 
Fusarium avenaceum;50  
Fusarium sp. FO-130510 Cytotoxic against Hep G2, MRC-5; ACAT inhibition 
A2 (5) Fusarium avenaceum50 Cytotoxic against Hep G2, MRC-5 
B (2) 
Fusarium avenaceum;50  
Fusarium sp. FO-1305;10 
Verticillium hemipterigenum13 
Cytotoxic against Hep G2, MRC-5; ACAT inhibition 
B1 (4) 
Fusarium avenaceum;50  
Fusarium sp. FO-130510 Cytotoxic against Hep G2, MRC-5; ACAT inhibition 
B2 (6) 
Fusarium acuminatum9 
A, A1, B, B1, B2, B4 
Cytotoxic against Hep G2, MRC-5; 
B3 (7) Fusarium acuminatum9 Cytotoxic against Hep G2, MRC-5 
B4=D (8) 
Because both were 
published in 1992 
Fusarium acuminatum;9  
Fusarium sp. FO-1305;10  
Verticillium hemipterigenum13 
ACAT inhibition 
C (9) Verticillium hemipterigenum
13 
B, B4, G, C Antimalarial, antituberculous, cytotoxic 
E1 (10) Fusarium sp. FO-130510 ACAT inhibition 
E2 (11) Fusarium sp. FO-130510 ACAT inhibition 
F (12) Fusarium sp. FO-130510 ACAT inhibition 
G (13) Halosarpheia sp. (strain732)
12 
B, B4 
Heps 7402 
Enniatin Biological sourcea Bioactivities 
H (14) Verticillium hemipterigenum
13 
B, B4, G, C 
Antimalarial, antituberculous, cytotoxic 
I (15) Verticillium hemipterigenum
13 
B, B4, G, C 
Antimalarial, antituberculous, cytotoxic 
MK1688 (16) Verticillium hemipterigenum
13 
B, B4, G, C 
Antimalarial, antituberculous, cytotoxic 
J1 (17) 
Fusarium sp. F3114 
B, B1, B2, B4 
Against Botrytis cinerea 
J2 (18) 
Fusarium sp. F3114 
B, B1, B2, B4 
Against Botrytis cinerea 
J3 (19) 
Fusarium sp. F3114 
B, B1, B2, B4 
Against Botrytis cinerea 
K1 (20) 
Fusarium sp. F3114 
B, B1, B2, B4 
Against Botrytis cinerea 
L (21) Unidentified fungus BCC2629
15 
B, B4, H, I 
Antimalarial, antituberculous, cytotoxic 
M1 (22) 
Unidentified fungus BCC262915 
B, B4, H, I 
Antimalarial, antituberculous, cytotoxic 
M2 (23) Unidentified fungus BCC262915 Antimalarial, antituberculous, cytotoxic 
N (24) Unidentified fungus BCC2629
15 
B, B4, H, I 
Antimalarial, antituberculous, cytotoxic 
O1 (25) 
Verticillium hemipterigenum11 
B, B4, G, C, H, I 
Antimalarial, antituberculous, cytotoxic 
O2 (26) 
Verticillium hemipterigenum11 
B, B4, G, C, H, I 
Antimalarial, antituberculous, cytotoxic 
O3 (27) 
Verticillium hemipterigenum11 
B, B4, G, C, H, I 
Antimalarial, antituberculous, cytotoxic 
P1 (28) 
Unidentified Fusarium sp. VI 
0344116 — 
P2 (29) 
Unidentified Fusarium sp. VI 
0344116 — 
Abbreviation: ACAT, acyl-CoA:cholesterol acyltransferase. 
aOther enniatins that were isolated simultaneously are listed as well, where appropriate. 
 
There are at least two other cyclohexadepsipeptides that resemble enniatins structurally, notably 
the destruxins17 and the beauvericins.18 What distinguishes these three is that the enniatins have 
alternating amino acid and hydroxy acid residues. Conversely, destruxins contain only one 
hydroxy acid and five amino acid residues, while beauvericins are comprised of alternating N-
methylphenylalanine and hydroxy acid residues. Although all three types of 
cyclohexadepsipeptides have gained attention, likely because of their range of interesting 
biological activities,19, 20 the chemistry and the wide-ranging biological activities of the enniatins 
have not been reviewed. 
 
Biosynthesis of enniatins 
 
The biosynthesis of enniatins was reviewed in 2002.21 Briefly, enniatins are biosynthesized by a 
347-kDa multifunctional enzyme, termed enniatin synthetase.22, 23 The initial biosynthetic step 
involves adenylation, which activates substrates as thioesters; this is followed by N-methylation 
and peptide bond formation. Once formed, the dipeptidol unit condenses with two other 
dipeptidols in an iterative fashion to form a linear hexadepsipeptide, which cyclizes in the final 
step to form the enniatin.24 Enniatin synthetase has low substrate specificity for L-amino acids, 
thus permitting incorporation of different amino acids and contributing to the chemical diversity 
of the enniatins (Figure 1). Despite variability in the amino acid units, distinct Fusariumstrains 
seem to incorporate preferentially some amino acids over others, as evidenced by the fact that 
certain enniatins can be isolated from only a particular species or strain of fungus. For 
example, Fusarium sambucinum preferably produces enniatin A (1), while Fusarium 
scirpi preferably makes enniatin B (2).25 The D-hydroxy acid units are incorporated via D-2-
hydroxyisovalerate dehydrogenase. This enzyme has high substrate specificity, as D-
hydroxyisovaleric acid is conserved in most enniatins, except for enniatins H (14), I (15), L (21), 
M1(22), M2 (23) and N (24) (Figure 1), and is present in most enniatin-producing fungi.26, 27 To 
date, most enniatins have been biosynthesized naturally from producing fungi; however, 
enniatins C (9), G (13) and MK1688 (16) were produced via precursor-directed biosynthesis.13 It 
is conceivable that as more advanced knowledge is generated on the biosynthesis of these 
compounds, other enniatins could be biosynthesized by altering the insertion of either (or both) 
the amino acid or hydroxy acid substrates. 
 
Chemistry: inseparable mixtures of enniatins 
 
Eighteen out of the 29 known enniatins have been isolated as single compounds. The other 11 
have been isolated as five mixtures of homologs (enniatins E (re-examined below as enniatin 
E1 (10) and E2(11)); J2 (18), J3 (19); M1 (22), M2 (23); O1 (25), O2 (26), O3 (27); and P1 (28), 
P2(29)), despite the use of modern chromatographic techniques. Thus, their structures were 
characterized as mixtures. 
 
Revisiting enniatin E 
 
In 1992, enniatins E1(10) and E2 (11) were the first reported inseparable mixture of enniatins 
(reported as enniatin E).10 Isolated with enniatins D (8) and F (12), the mixture of enniatins 
E1 (10) and E2 (11) was active as acyl-CoA:cholesterol acyltranferase inhibitor.28 These showed 
double the resonances in the NMR spectra when compared with enniatins D and F. The 
authors10 reported this as a mixture of two nonequivalent isomers after noting two key 
observations: (1) failing to see any interconvertible spots on a silica gel TLC plate even at higher 
temperature, and (2) verifying by chemical degradation the amino acid and hydroxy acid 
components. While two homologs were proposed, a more efficient method is proposed below 
that serves to verify the identities based on MS without the need for chemical degradation and 
illustrates, in general, some of the practical challenges of working with enniatin homologs. The 
difficulties in isolating and elucidating the individual components in the mixtures are oftentimes 
understated in the literature and, in our experience, daunting. 
 
 
Enniatin R1 R2 R3 R4 R5 R6 
A (1) sBu sBu sBu iPr iPr iPr 
A1 (3) sBu iPr sBu iPr iPr iPr 
A2 (5) sBu iBu sBu iPr iPr iPr 
B (2) iPr iPr iPr iPr iPr iPr 
B1 (4) iPr sBu iPr iPr iPr iPr 
aB2 (6) iPr iPr iPr iPr iPr iPr 
aB3 (7) iPr iPr iPr iPr iPr iPr 
B4 = D (8) iPr iPr iBu iPr iPr iPr 
C (9) iBu iBu iBu iPr iPr iPr 
*E1 (10) iPr iBu sBu iPr iPr iPr 
*E2 (11) iPr sBu iBu iPr iPr iPr 
F (12) iBu sBu sBu iPr iPr iPr 
G (13) iBu iBu iPr iPr iPr iPr 
H (14) iPr iPr iPr sBu iPr iPr 
I (15) iPr iPr iPr sBu sBu iPr 
MK1688 (16) iPr iPr iPr sBu sBu sBu 
J1 (17) iPr iPr Me iPr iPr iPr 
*J2 (18) sBu iPr Me iPr iPr iPr 
*J3 (19) Me iPr sBu iPr iPr iPr 
K1 (20) iPr iPr Et iPr iPr iPr 
L (21) iPr iPr iPr iPr iPr Hy-sBu 
*M1 (22) iPr iPr iPr iPr sBu Hy-sBu 
*M2 (23) iPr iPr iPr iPr Hy-sBu sBu 
N (24) iPr iPr iPr sBu sBu Hy-sBu 
*O1 (25) iBu iPr iPr sBu iPr iPr 
*O2 (26) iBu iPr iPr iPr sBu iPr 
*O3 (27) iBu iPr iPr iPr iPr sBu 
*bP1 (28) iPr iPr Hy-Et iPr iPr iPr 
*bP2 (29) iBu iPr Hy-Et iPr iPr iPr 
aB2 and B3 have one and two N-Methyls, respectively, in the R1 and the R1 and R2 positions. 
bThe stereochemistry of the Hy-Et side chain was not determined.16 
*Homologous among enniatins with the same “letter”. 
Figure 1. Enniatins and their amino acid and hydroxy acid compositions. 
 
Recent studies on enniatins E1 (10) and E2 (11) emerged in our ongoing program to examine 
filamentous fungi for anticancer drug leads,29, 30 when promising cytotoxicity was observed in an 
extract of culture MSX 44957 (Fusarium sp., sequence deposited in Genbank (JQ809513)). This 
extract yielded dipeptidols 30 and 31 (discussed below) and enniatins B1(4), D (8) and I (15). An 
additional compound, pseudo-enniatin E, was isolated as well that behaved like a dimer of 
enniatins, as it displayed twice the number of expected resonances in the 1H and 13C NMR 
spectra when compared with compounds 4, 8 and 15, and generated a quasi molecular ion 
of m/z=1335, essentially twice the mass of most enniatins. Importantly, this compound displayed 
a single peak when examined with at least eight different HPLC/UPLC columns, including both 
normal- and reverse-phase chemistries and a chiral column and via testing a suite of solvent 
conditions (examples are illustrated in Figure 2). These observations led to a tentative initial 
structure with double the number of amino acids and hydroxy acids of the known enniatins, 
although there were some challenges using 2D NMR experiments to finalize the structure. 
However, upon re-running and re-analyzing the mass spectral data, a consistent molecular ion 
was observed at m/z=668 for (M+H)+. These data were acquired independently in two different 
MS laboratories, and we suspect that the initial observation of m/z=1335 was an artifact, likely 
representing (2M+H)+. The molecular ion matched seven known enniatins in literature: A1 (3), 
E1 and E2 (10 and 11), G (13), I (15), and O1 (25), O2 (26), O3 (27). Of these, the enniatin O 
homologs could be ruled out, as they were described as a mixture of three inseparable 
homologs,11 and our NMR data displayed patterns that were most similar to enniatins E1 (10) and 
E2 (11), although the original paper reported it as simply enniatin E.10 
 
 
Figure 2. Representative profile of enniatin E homologs when examined using an Acquity UPLC 
(Waters Corp., Milford, MA, USA) and a solvent system of 20–100% MeOH-H2O using four 
different columns (all from Waters Corp.): (a) HSS-C18 (1.8 μm; 50 × 2.1 mm); (b) BEH-C18 
(1.7 μm; 50 × 2.1 mm); (c) BEH-Phenyl (1.7 μm; 50 × 2.1 mm); (d) HSS-T3 (1.8 μm; 100 × 
2.1 mm). 
 
Table 2. NMR data for Enniatin E1 (10) and E2(11) (500 MHz in Acetone-d6 and CDCl3)a  
Acetone-d6 CDCl3 
Position δH, Multiplicity (J in Hz) δC δH, Multiplicity (J in Hz) δC 
Hiv1 
 1 — 170.3 — 170.5 
 2 5.15, d (9.0) 75.0/74.9 4.95, d (9.0) 77.2 
 3 2.18–2.22, m 30.0 2.20–2.30, m 30.4 
 4 0.92–0.98, m 18.9 0.88–0.99, m 19.1 
 5 0.92–0.98, m 18.7 0.88–0.99, m 19.0 
          
N-MeVal 
 6 — 169.0/168.6 — 170.2 
 7 4.88/4.51, d (10) 60.8/62.5 4.91, d (9.5) 61.3 
 8 2.18–2.22, m 31.9 2.02, m 33.6 
 9 0.92–0.98, m 20.6 0.88–0.99, m 20.2 
 10 0.92–0.98, m 19.4 0.88–0.99, m 19.6 
 N-Me 3.13, s 30.9/32.3 3.14, s 34.3 
          
Hiv2 
 11 — 170.8/170.7 — 170.4 
 12 5.15, d (9.0) 74.7/74.4 5.10, d (8.0) 75.3 
 13 2.18–2.22, m 29.8 2.20–2.30, m 30.0 
 14 0.92–0.98, m 18.0 0.88–0.99, m 20.2 
 15 0.92–0.98, m 18.0 0.88–0.99, m 19.2 
          
N-MeIle 
 16 — 169.1/168.7 — 168.7 
 17 5.01/4.71, d (10) 59.1/60.5 5.04, d (10) 59.8 
 18 2.03, m 33.9 2.20–2.30, m 30.0 
 19 0.92–0.98, m 17.7 0.88–0.99, m 16.0 
 20 2.18–2.22, m 24.9 2.20–2.30, m 27.8 
 21 0.84–0.89, m 9.8/10.2 0.83–0.87, m 11.1 
 N-Me 3.10/3.11, s 30.8/31.9 3.11, s 33.8 
          
Hiv3 
 22 — 169.3/169.4 — 170.9 
 23 5.29/5.25, d (8.0) 74.5/74.4 5.20, d (9.0) 75.5 
 24 2.18–2.22, m 30.3 2.20–2.30, m 30.0 
 25 0.92–0.98, m 18.2 0.88–0.99, m 19.6 
 26 0.92–0.98, m 18.1 0.88–0.99, m 18.9 
          
N-MeLeu 
 27 — 170.2/170.4 — 169.0 
 28 5.10, d (10) 54.6/54.4 4.57, m 57.3 
 29 1.85, m;1.64, m 37.5 1.80, m; 1.74, m 38.1 
 30 1.52, m 24.8 1.53, m 25.5 
 
Acetone-d6 CDCl3 
Position δH, Multiplicity (J in Hz) δC δH, Multiplicity (J in Hz) δC 
 31 1.02, m 19.7 1.01, d (7.0) 20.5 
 32 1.45, m 25.2 1.35, m 25.0 
 N-Me 3.15/3.16, s 31.4/31.5 3.07, s 31.9 
Abbreviations: Hiv, hydroxyisovaleric acid; N-Me, N-methyl; N-MeVal, N-methyl valine; N-MeIle, N-methyl 
isoleucine; N-MeLeu, N-methyl leucine. 
aValues before and after slashes are chemical shifts for the individual homologs. 
 
 
Figure 3. 1H NMR profile of enniatin E homologs (α-proton region) at three temperatures in 
DMSO-d6(500 MHz). 
 
To further characterize this isolated compound, and compare and contrast differences with the 
literature on enniatin E1 (10) and E2 (11),10 a full suite of 1- and 2D NMR data were acquired in 
different solvents, including CD3OD, DMSO-d6, CDCl3 and acetone-d6, to see whether better 
resolution could be achieved. NMR data (Table 2) acquired in acetone-d6 resulted in 1H NMR 
signals that were more spread out and better resolved. However, 1H NMR data in the 
literature10 were acquired in CDCl3 and compared favorably with the data on “pseudo-enniatin 
E” acquired also in CDCl3. 13C NMR data in acetone-d6 also yielded the best data set, followed 
by DMSO-d6, as most of the α-carbon resonances were individual peaks (12 peaks in acetone-d6, 
as opposed to just six resonances when analyzed in CDCl3 (Table 2)). DMSO-d6, with a b.p. of 
189 °C, was utilized for variable-temperature NMR experiments, which permitted NMR spectra 
acquisition at higher temperatures, as compared with other more volatile NMR solvents. The 
variable-temperature NMR experiments probed whether the compounds were a result of 
conformers (if signals coalesce at higher temperature)31 or homologous (if coalescence was not 
observed at any point as the temperature was elevated). In the case of the pseudo-enniatin E, 
coalescence was not observed. In fact, at some higher temperatures, the peaks appeared even 
sharper than at room temperature (Figure 3), further evidence that pseudo-enniatin E was a 
mixture of homologs and not conformers. 
 
To determine the configuration of pseudo-enniatin E, acid hydrolysis was performed using 
methods described previously.32 The sample was extracted thrice with CH2Cl2, and both the 
aqueous and organic extracts were subjected to chiral HPLC analyses by comparing them with 
standards, which demonstrated that pseudo-enniatin E had the same composition of amino acids 
and hydroxy acids, all with the same configurations, as enniatins E1 (10) and E2 (11) (Hiv, N-
MeIle and N-MeLeu). 
 
Analysis of the mass fragmentation (Figure 4) through MSn experiments for pseudo-enniatin E 
(m/z=690 (M+Na)+) showed fragments consistent with the sequential loss of N-MeIle or N-
MeLeu (the two amino acids being isomeric (m/z=563)), Hiv (m/z=463), N-MeVal (m/z=350) 
and another Hiv (m/z=250). As enniatins have alternating amino acid and hydroxy acid residues, 
the initial sequential loss of residues revealed that N-MeVal was flanked by two Hiv units. The 
Hiv units had to be flanked by the two other amino acid residues—N-MeIle and N-MeLeu—
which in turn were separated by one last Hiv unit. A second pattern emerged from the same mass 
spectrum that displayed sequential loss of N-MeVal (m/z=577), followed by Hiv+NMeLeu 
(or NMeIle) (m/z=350). Hence, in order for enniatin E to display double the resonances in the 
NMR spectra, the two homologs, which we now suggest should be termed enniatin E1 (10) and 
E2 (11) (Figure 1), had the following cyclic order: (1) N-MeIle-Hiv-N-MeVal-Hiv-N-MeLeu-Hiv 
(E1) and (2) N-MeLeu-Hiv-N-MeVal-Hiv-N-MeIle-Hiv (E2) (Figure 4). 
 
 
Figure 4. MSn mass fragmentation of homologs of enniatin E. The boxes and circles highlight 
where N-MeIle and N-MeLeu were reversed in the two homologs. 
 
Isolation of 1,4-perhydrooxazine-2,5-dione compounds 30 and 31 
 
Two other compounds (30 and 31) were isolated together with the enniatins from the 
same Fusarium species (MSX 44957). These dipeptidols, characterized based on HRESIMS and 
NMR data (Table 3), may represent building blocks of enniatins in cyclized form.33 
Compound 30 showed m/z=214.1452 (M+H)+, corresponding to a molecular ion of 
C11H19NO3 (calculated for C11H20NO3; 214.1438), while compound 31 showed m/z=228.1599 
(M+H)+, corresponding to a molecular ion of C12H21NO3 (calculated for C12H22NO3; 228.1594). 
To the best of our knowledge, there are no reports on the isolation of these as natural products, 
although compound 30 was obtained as a by-product upon hydrolysis and lactonization of N-α-
bromoisovaleryl-N-MeVal in a synthesis paper.33 
 
Table 3. NMR data for compounds 30 and 31 (500 MHz in CDCl3) 
 
  
Position δH, Multiplicity (J in Hz) δC δH, Multiplicity (J in Hz) δC 
1 — 170.4 — 170.3 
2 4.47, d (9.0) 63.5 4.66, d (9.0) 61.8 
3 — 169.4 — 169.2 
4 5.11, d (8.0) 75.9 5.15, d (9.0) 75.6 
5 2.27, m 28.1 2.08, m 34.0 
6 0.86, d (7.0) 19.5 1.45, m; 1.11, m 25.3 
7 1.03, d (7.0) 18.9 1.00, d (7.0) 16.3 
8 — — 0.89, t (8.0) 11.0 
9 2.27, m 30.1 2.30, m 29.9 
10 0.96, d (7.0) 20.7 1.02, d (7.0) 18.7 
11 0.93, d (7.0) 18.7 0.97, d (7.0) 18.5 
12 3.10, s 33.5 3.13, s 33.1 
 
There are likely several plausible explanations for the existence of these dipeptidols in cultures 
of MSX 44957. Compounds 30 and 31 could be synthesized by a mutated enzyme, where instead 
of proceeding to an elongation step, the enzyme terminates the process and cyclizes at the 
dipeptidol stage. One could envisage them as the result of limited substrates, although we never 
limited nutrients intentionally. Alternatively, they may have formed spontaneously owing to 
thermodynamically stable six-membered rings or could be a by-product of metabolism. 
Regardless, their identification concomitant with a series of enniatins may be valuable for future 
biosynthetic considerations. 
 
Structure elucidation: techniques and challenges 
 
The structures of the enniatins have been determined by a variety of physical and chemical 
methods. With respect to X-ray crystallography, only enniatins B (2)34 and N (24)15 have been 
reported in the literature. Alternatively, the use of NMR spectroscopy is more prominent. The 
18-membered cyclic backbone of all enniatins consists of carbonyl carbons (three amides and 
three esters) and six α-carbons, three of which are oxygenated (δC 73∼77 p.p.m.) and three of 
which are connected to nitrogen atoms (δC 56∼65 p.p.m.). An α-proton (δH 4.44∼5.32 p.p.m.) is 
connected to each α-carbon in the backbone, while a methyl group is connected to each nitrogen 
in the amino acid portion (δH 3.08∼3.18 p.p.m.), except for enniatins B2 and B3, which have one 
and two less N-methyl moieties, respectively.9 The connectivities of each amino and hydroxy 
acid residue are established by HMBC data, which typically show correlations from the α-
protons to two carbonyl carbons, and from the N-methyl protons to the ester carbonyl carbon that 
acylates that particular amino acid. The identity of each residue can be determined by COSY and 
TOCSY data and by multiplicities and J-values. Although signals for the methyl groups of Val, 
Leu, and Ile are typically overlapped in an enniatin 1H NMR spectrum, a careful integration of 
the area will facilitate counting the number of methyl groups in the structure, and these are 
reported typically as interchangeable values. The chemical shifts of the β-protons for amino acids 
depend on whether the structure has a Val (δH 2.20∼2.30 p.p.m.), Leu (δH 1.70∼1.80 p.p.m.), or 
Ile (δH 2.09∼2.11 p.p.m.). The multiplicity of an α-proton of an Ile (triplet) would also appear 
different from that of a Leu (doublet) or Val (doublet). Moreover, the β-carbon of Ile differs in 
chemical shift from Leu (δC 33∼35 p.p.m. vs 37∼38 p.p.m., respectively). Also, the DEPT-135 
experiment can differentiate between Ile and Leu based upon the chemical shift of the carbon 
that changed phase. Biosynthetic considerations can also assist in the structure elucidation 
process. Although the enniatin synthases were mentioned to have low substrate specificity for L-
amino acids, a study also showed that this enzyme preferentially incorporates only certain sizes 
of amino acid side chains.24 Thus, alanine and α-aminobutyric acid are the only other amino 
acids shown to be incorporated into a naturally produced enniatin, specifically enniatins J1 (17), 
J2 (18), J3 (19) and K1 (20).14 In summary, if the enniatin will not form crystals suitable for X-ray 
analysis, NMR spectroscopy may be the best solution, although the spectrum will appear 
crowded and overlapped in certain diagnostic regions. Focusing on how resonances can be 
ascribed to distinct amino acid or hydroxy acid residues, particularly Val, Leu, Ile and Hiv, 
should narrow the work involved considerably. 
 
The modern challenge in the structure elucidation of enniatins arises when homologs are 
isolated. These enniatins co-elute and appear as a single peak in chromatographic separations 
(for example, Figure 2), even using modern stationary phases, a suite of mobile phases, and even 
a chiral column. As inseparable mixtures, they display double (as exhibited by enniatins E1/E2, 
J2/J3 and M1/M2) or triple (as shown by enniatins O1/O2/O3) the resonances in the NMR 
spectra.10, 11, 14, 15 In these situations, neither a change in solvent nor the use of variable 
temperature experiments results in simplification of resonances or coalescence of signals, thus 
ruling out the possibility of conformational isomers, as shown with compounds like 
bassianolide.31 Also, mass spectral data suggest a MW in the range of typical enniatins (that is, 
611–683 a.m.u.). For certain enniatins, the structures of such homologs were elucidated in 
different ways, and a few cogent examples are discussed below. 
 
Enniatin J2/J3 
 
In conjunction with NMR data, MS had a key role in the structure elucidation of enniatins J2 (18) 
and J3 (19), particularly the use of ESIMSnto determine the sequence of residues.14 Isolated 
together with enniatins J1 (17) and K1 (20) from an unidentified Fusarium strain, these homologs 
displayed a m/z of 626.3972 (M+H)+. NMR data and fragmentation information via 
ESIMS2, 3, 4 indicated the presence of N-MeAla (m/z=85), N-MeVal (m/z=113), N-MeIle 
(m/z=127) and Hiv (m/z=100). The sequence was determined by subjecting the homologs to 
partial acid hydrolysis to obtain linear depsipeptides, which generated two major fractions that 
were subjected to further ESIMSn. One fraction displayed the sequential loss of N-MeIle 
followed by N-MeAla, after the initial loss of Hiv. Keeping in mind that enniatins have 
alternating amino acid-hydroxy acid residues, these results indicated that N-MeIle and N-MeAla 
had to be on opposite ends of the linear depsipeptide and that N-MeVal separated both amino 
acids. In support of this finding, the other fraction showed a loss of N-MeVal followed by N-
MeAla, after the initial loss of Hiv. Using the same logic, the N-MeIle had to be between N-
MeVal and N-MeAla. Coupling these finding together distinguished the sequences of the two 
homologs (Figure 1). 
 
Enniatin M1/M2 
 
Isolated from an unidentified fungus and reported as one of the first enniatins with a hydroxyl 
group in the side chain of the Hiv portion of the structure (the others being enniatins L (21) and 
N (24)), enniatins M1(22) and M2 (23) were isolated as a single peak by reversed phase 
HPLC.15 However, this isolate displayed twice the expected resonances in both the 1H- and 13C-
NMR spectra for a single enniatin molecule. Extensive 1- and 2D NMR analyses revealed that 
these homologs contained six units of N-MeVal, two units of Hiv, two units of 2,3-dihydroxy-3-
methylpentanoic acid, and two units of 2-hydroxy-3-methylpentanoic acid (Hmp). Even though 
there was no direct evidence for the exact sequence of residues for homologs M1 (22) and 
M2 (23), the authors suggested that there had to be a difference in their connectivities in order for 
these two homologs to display different NMR resonances. Indirectly, the NMR data from the 
related compound, enniatin N (24),15 from which a crystal structure was obtained, showing the 
presence of 2,3-dihydroxy-3-methylpentanoic acid and 2-hydroxy-3-methylpentanoic acid 
residues in the hydroxy acid portion of the molecule, were used to match the resonances 
observed in enniatins M1(22) and M2 (23) (Figure 1). 
 
Enniatin O1/O2/O3 
 
Showing not just two but three sets of NMR resonances, enniatins O1(25), O2 (26) and O3 (27) 
were obtained from Verticillium hemipterigenum, whose fermentation conditions were optimized 
for enniatin production.11 NMR data (both 1H and 13C spectra) revealed that these homologs 
consisted of six N-MeVal, three N-MeLeu, six Hiv and three Hmp residues. Further structural 
analyses by NMR and MS were performed on four amide fragments, produced from partial 
degradation using LiBH4 followed by acetylation. The 1H- and 13C-NMR data of the fragments 
matched similar data obtained from known enniatins (B (2), B4 (8), and H (14)) subjected to the 
same reaction. In short, the absolute configuration and the sequences of the amino and hydroxy 
acid residues were derived by comparison with known compounds and by mass spectral analyses 
of the fragments, thus establishing the structures for enniatins O1 (25), O2 (26) and O3 (27). 
 
Identification of the configuration of the amino acid and hydroxy acid residues 
 
The amino acid residues in all of the 29 enniatins described to date have the L-configuration, 
likely because the biosynthetic enzyme, enniatin synthetase, has a preference over the D-isomer. 
In a similar fashion, all of the hydroxy acids have the D-configuration, possibly owing to the 
preference of the D-2-hydroxyisovalerate dehydrogenase. Although some of the enniatin 
literature is scant on experimental results, it may be a fair assumption, at least initially, that 
the L-amino acids and D-hydroxy acids are incorporated based largely on biosynthetic 
considerations. However, a simple acid hydrolysis can be performed on just a milligram quantity 
of the material and compared with standards using a chiral column (see discussion of enniatin 
E1 (10) and E2 (11)). In this way, no derivatizations are required that would diminish the yield of 
the “product”. Moreover, in cases where inseparable homologs are present, acid hydrolysis can 
help determine the identity of the residues (see discussion of enniatin E1 (10) and E2 (11)). Also, 
partial degradation using LiBH4 followed by acetylation with acetic anhydride yielded fragments 
that were analyzed by NMR and MS, as exemplified by enniatins O1 (25), O2 (26) and 
O3 (27).10 In summary, although the biosynthetic considerations for the configuration of the 
residues have been consistent for 29 enniatins, to date, taking the research a step further and 
determining the configurations experimentally is straight forward and should be pursued; 
compounds with an unanticipated configuration could be uncovered in the future. 
 
Biological activities 
 
Antimicrobial activities 
 
Enniatins have been shown to exhibit a wide array of biological activities, and one of the earliest 
reported was antimicrobial activity towards Mycobacterium spp., Staphylococcus spp., Bacillus 
spp., Pseudomonas aeruginosa and Escherichia coli.1, 35, 36 Enniatins B (4), B4(8), H (14), I (15), 
G (13), C (9), MK1688 (16), O1 (25), O2 (26) and O3 (27) were shown to inhibit the activity of 
Mycobacterium tuberculosis.11, 13 Furthermore, a recent study focused on the ability of enniatins 
to inhibit mycotoxigenic molds, such as Fusarium verticillioides, F. sporotrichioides, F. 
oxysporum, F. poae, F. tricinctum, F. proliferatum, Beauveria bassiana, Trichoderma 
harzianum, Aspergillus flavus, A. parasiticus, A. fumigatus, A. ochraceus and Penicillium 
expansum.37 Interestingly, of the four enniatins used in that study (A (1), A1 (3), B (4), B1 (4)), 
only enniatin B (2) displayed inhibition of some of the molds. Enniatins were also tested against 
Botrytis cinerea, a fungal phytopathogen that causes gray mold to many host species and infects 
seedlings stored in humid conditions. Of the series of enniatins tested, enniatins B (2), B4 (8) and 
K1 (20) were found to partially inhibit spore germination of B. cinerea.14 
 
One mixture of enniatins, obtained from Fusarium lateritium WR, strain 437,38 has been 
developed as an antimicrobial, fusafungine, and is administered as a topical treatment of upper 
respiratory tract infections by oral and/or nasal inhalation.38 The drug is sold under the trade 
names Locabiotal (United Arab Emirates and Taiwan), Bioparox (Poland and Slovakia), 
Locabiosol (USA and Canada) and Fusaloyos (Spain) and is manufactured by Laboratoires 
Servier, a French pharmaceutical company. Fusafungine showed bacteriostatic activity against a 
suite of microorganisms, such as Mycoplasma pneumoniae, Legionella pneumophila, 
Streptococcus pneumoniae, S. pyogenes and Staphylococcus aureus, including methicillin-
resistant S. aureus. 
 
Enzyme inhibitors 
 
Enniatins A (1), A1 (3), B (2), B1 (4), D (8), E1/E2 (10 and 11) and F (12) have been probed, at 
least in a limited fashion, as enzyme inhibitors, particularly acyl-CoA:cholesterol 
acyltransferase, although their activities were moderate compared with beauvericin, one of the 
most potent acyl-CoA:cholesterol acyltransferase inhibitors of microbial origin.28 Nevertheless, 
such inhibitions could be significant in the treatment and prevention of atherosclerosis and 
hypercholesterolemia. In a separate study, the hypolipidaemic action of enniatin B (2) could be 
ascribed both to acyl-CoA:cholesterol acyltransferase inhibition and a reduction of triglyceride 
synthesis, thus diminishing the pool of the free fatty acid in cells.39 Also, enniatin B (2) was 
found to inhibit 3′,5′-cyclo-nucleotide phosphodiesterase and was able to bind calmodulin.40, 41 
This mode of action suggested an altering of signal transduction mechanisms of enzymes that are 
dependent on calmodulin, such as cyclic nucleotidase and protein kinases. In summary, although 
the number of studies of enniatins vs enzymes is somewhat limited, they seem to possess 
activities that warrant further exploration. 
 
Cytotoxicity and anticancer properties 
 
Towards cancer research, a study found enniatins B (2), B1 (4), and D (8) to inhibit pleiotropic 
drug resistance 5 protein, an ATP-binding cassette that is one of the major causes of drug 
resistance against a variety of compounds, including drugs like tamoxifen and doxorubicin.42 
While many inhibitors of multidrug resistance proteins have been described, these enniatins are 
important because they are found to be potent and specific for pleiotropic drug resistance 5 
protein but are less toxic than other such leads.42 In another cancer-related study, enniatins A1 (3) 
and B1 (4) were found to induce apoptotic cell death and disrupt extracellular-regulated protein 
kinase, a mitogen-activated protein kinase associated with cell proliferation,43 while a mixture of 
enniatins A (1), A1 (3), B (2) and B1 (4) also induced apoptosis in several human cancer cell lines 
at low molar concentrations after 24 h of treatment.44 
 
Our studies on enniatins were initiated on the basis of cytotoxicity of an extract of the 
fungus Fusarium sp. (MSX 44957) tested against a panel of three human cell lines in culture (the 
methods and strategy for such studies have been outlined previously).32, 45 As described earlier in 
this manuscript, a series of compounds were isolated and characterized, including enniatins 
E1 (10), E2 (11), B1 (4), D (8), I (15) and compounds 30 and 31. Of these, the enniatins were 
more potent than the related building blocks, that is, compounds 30 and 31, with the homolog 
mixture of enniatins E1 (10) and E2 (11) being the most potent (see Table 4). Despite these 
encouraging results, the activity of the enniatins was still approximately one to two orders of 
magnitude less potent than the positive control, camptothecin. 
 
Table 4. Cytotoxicity of enniatins and other compounds isolated from Fusarium sp. (MSX 
44957) against a panel of human tumor cell lines 
 IC50 values (in μM)a 
Compound MCF-7 H460 SF268 
Enniatin B1 (4) 1.4 1.2 2.2 
Enniatin E1/E2 (10/11) 0.5 0.7 2.6 
Enniatin D (8) 2.7 2.8 4.0 
Enniatin I (15) 1.0 1.3 1.4 
30 8.4 8.9 10 
31 3.4 3.2 4.3 
Camptothecinb 0.07 0.008 0.50 
aIC50 values were determined as the concentration required to reduce cellular proliferation by 50% relative to 
untreated controls following 72 h or continuous exposure using methods described in detail previously.51,52 
bPositive control. 
 
Other biological activities 
 
Not surprising for a series of compounds first described in the 1940s, the enniatins have shown a 
variety of other biological activities; a recent review highlights several others not covered in this 
manuscript.46 In particular, enniatin A (1) was shown to possess anthelmintic properties 
against Nippostrongylus brasiliensis, Trichinella spiralis and Heterakis spumosa.47 Moreover, 
analogs of enniatin A (1) were synthesized, and two new derivatives were shown to possess 
strong in vivo activity against H. contortus in sheep.48 A mixture of enniatins A (1), A1 (3), B (2), 
B1 (4) was cytotoxic against the Spodoptera frugiperda cell line, which is an insect cell line used 
to probe for in vivocytotoxicity of fungal metabolites.49 Several of the enniatins (B (2), B4(8), H 
(14), I (15), G (13), C (9), MK1688 (16), O1 (25), O2 (26) and O3 (27)) were found to inhibit 
proliferation of the human malaria parasite Plasmodium falciparum.11, 13 Given this diverse range 
of activities, future researchers should be encouraged to examine the enniatins against a broad 
range of biological targets. 
 
Enniatins as ionophores 
 
Given the pore shape of the cyclodepsipeptide core of enniatins, their ionophoric behavior has 
been suggested since the 1960s.50 More recently, a study on the electrophysiological properties 
of an enniatin mixture containing A (1), A1 (3), B (2), B1 (4) revealed that they incorporate easily 
into the cell membrane as a passive channel and form cation selective pores.40 By forming 
complexes with cations like K+, Na+and Ca2+, enniatins evoke changes in intracellular ion 
concentration, disrupting cell function. Indeed, this may explain the broad range of biological 
activities observed for the enniatins. 
 
Conclusion 
 
Enniatins are secondary metabolites that have an interesting cyclohexadepsipeptide structure and 
that are produced, primarily, by Fusarium species of fungi. Although 29 of these have been 
described in the literature, it is anticipated that other analogs exist in nature, particularly given 
the diverse biosynthetic possibilities in the side chains of these compounds. Moreover, mixtures 
of homologs, where the position of amino acid units have been shuffled, will continue to 
challenge the skills and resolve of natural products chemists. Studies on these compounds have 
been, and likely will be in the future, driven by their broad range of biological activities. To date, 
one pharmaceutical product, fusafungine, has been derived from the enniatins; the future awaits 
other applications. 
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